RNS Number : 9788L
EKF Diagnostics Holdings PLC
18 May 2022
 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Result of AGM and Voting results

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The voting results of the AGM were as follows:

 


For

Against

Withheld

Resolution

Votes

%

Votes

%

Votes

1

297,230,867

99.97

19,436

0.01

93,775

2

297,118,498

99.93

149,199

0.05

76,381

3

297,238,261

99.97

29,436

0.01

76,381

4

297,193,761

99.96

71,936

0.02

78,381

5

297,119,554

99.93

148,143

0.05

76,381

6

236,784,981

95.1

12,138,597

4.88

48,420,500

7

288,404,713

97

8,859,820

2.98

79,545

8

287,755,016

96.78

9,512,681

3.2

76,381

9

297,247,711

99.97

19,436

0.01

76,931

10

297,186,561

99.95

81,136

0.03

76,381

11

284,734,398

95.77

12,531,299

4.21

78,381

12

282,197,437

99.95

97,136

0.03

15,049,505

 

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Mike Salter, CEO

 Tel: +44 (0)29 2071 0570

Marc Davies, CFO




Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas




Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams / Ben Farrow




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 

Point-of-Care

Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.

 

Central Laboratory

Clinical chemistry, Small lab analysers, Centrifuges

Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin

 

Life Sciences

Enzyme fermentation, Custom products and Bulk fermentation

 

Contract Manufacturing 

Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits

 

Laboratory Services

In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.

 

EKF's growth strategy to 2024 and beyond can be summarised as:

continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships;

investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses;

expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and

identify complementary earnings-enhancing acquisitions with key strategic value.

 

EKF will also continue to generate enhanced shareholder value through:

a progressive dividend policy; and

its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSFAFEAEESEFI
admin Result of AGM 32686762 A Wed, 05/18/2022 - 13:25 LSE RNS Results and Trading Reports EKF